Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors

被引：37

作者：

Dai, Yujia ^{[1
]}

Hartandi, Kresna ^{[1
]}

Soni, Niru B. ^{[1
]}

Pease, Lori J. ^{[1
]}

Reuter, David R. ^{[1
]}

Olson, Amanda M. ^{[1
]}

Osterling, Donald J. ^{[1
]}

Doktor, Stella Z. ^{[1
]}

Albert, Daniel H. ^{[1
]}

Bouska, Jennifer J. ^{[1
]}

Glaser, Keith B. ^{[1
]}

Marcotte, Patrick A. ^{[1
]}

Stewart, Kent D. ^{[1
]}

Davidsen, Steven K. ^{[1
]}

Michaelides, Michael R. ^{[1
]}

机构：

[1] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 01期

关键词：

D O I：

10.1016/j.bmcl.2007.10.018

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Tumor angiogenesis is mediated by KDR and other VEGFR and PDGFR kinases. Their inhibition presents an attractive approach for developing anticancer therapeutics. Here, we report a series of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. A number of compounds have been identified to be orally bioavailable and efficacious in the mouse edema model. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：386 / 390

页数：5

共 14 条

[1] Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor [J].

Albert, DH ;

Tapang, P ;

Magoc, TJ ;

Pease, LJ ;

Reuter, DR ;

Wei, RQ ;

Li, JL ;

Guo, J ;

Bousquet, PF ;

Ghoreishi-Haack, NS ;

Wang, B ;

Bukofzer, GT ;

Wang, YC ;

Stavropoulos, JA ;

Hartandi, K ;

Niquette, AL ;

Soni, N ;

Johnson, EF ;

McCall, JO ;

Bouska, JJ ;

Luo, Y ;

Donawho, CK ;

Dai, YJ ;

Marcotte, PA ;

Glaser, KB ;

Michaelides, MR ;

Davidsen, SK .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (04) :995-1006

[2]

BERGSLAND E, 2004, K AM J HEALTH SYS S5, V6, P5

[3] Vascular endothelial growth factor as a therapeutic target in cancer [J].

Bergsland, EK .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (21) :S4-S11

[4] Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents [J].

Bilodeau, MT ;

Fraley, ME ;

Hartman, GD .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) :737-745

[5] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

[6] Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors [J].

Dai, YJ ;

Guo, Y ;

Frey, RR ;

Ji, ZQ ;

Curtin, ML ;

Ahmed, AA ;

Albert, DH ;

Arnold, L ;

Arries, SS ;

Barlozzari, T ;

Bauch, JL ;

Bouska, JJ ;

Bousquet, PF ;

Cunha, GA ;

Glaser, KB ;

Guo, J ;

Li, JL ;

Marcotte, PA ;

Marsh, KC ;

Moskey, MD ;

Pease, LJ ;

Stewart, KD ;

Stoll, VS ;

Tapang, P ;

Wishart, N ;

Davidsen, SK ;

Michaelides, MR .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (19) :6066-6083

[7] Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor [J].

Dai, Yujia ;

Hartandi, Kresna ;

Ji, Zhiqin ;

Ahmed, Asma A. ;

Albert, Daniel H. ;

Bauch, Joy L. ;

Bouska, Jennifer J. ;

Bousquet, Peter F. ;

Cunha, George A. ;

Glaser, Keith B. ;

Harris, Christopher M. ;

Hickman, Dean ;

Guo, Jun ;

Li, Junling ;

Marcotte, Patrick A. ;

Marsh, Kennan C. ;

Moskey, Maria D. ;

Martin, Ruth L. ;

Olson, Amanda M. ;

Osterling, Donald J. ;

Pease, Lori J. ;

Soni, Niru B. ;

Stewart, Kent D. ;

Stoll, Vincent S. ;

Tapang, Paul ;

Reuter, David R. ;

Davidsen, Steven K. ;

Michaelides, Michael R. .

JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (07) :1584-1597

[8] Targeting c-kit mutations in solid tumors:: Scientific rationale and novel therapeutic options [J].

Demetri, GD .

SEMINARS IN ONCOLOGY, 2001, 28 (05) :19-26

[9] Angiogenesis as a therapeutic target [J].

Ferrara, N ;

Kerbel, RS .

NATURE, 2005, 438 (7070) :967-974

[10] Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy [J].

Lin, EY ;

Nguyen, AV ;

Russell, RG ;

Pollard, JW .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (06) :727-739

← 1 2 →